{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=11&sponsor=Pfizer",
    "query": {
      "sponsor": "Pfizer",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 3276,
    "total_pages": 328,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=12&sponsor=Pfizer&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=10&sponsor=Pfizer&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T22:14:19.431Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01844804",
      "title": "A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06438179",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Remicade",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 146,
      "start_date": "2013-05",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-01-07",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844804"
    },
    {
      "nct_id": "NCT00141284",
      "title": "An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "nelfinavir 1,250 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine 300 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine 150 mg twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-10",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2011-05-16",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141284"
    },
    {
      "nct_id": "NCT00571064",
      "title": "The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Mild to Severe Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Donepezil HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2008-01",
      "completion_date": "2009-04-22",
      "has_results": true,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carson",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571064"
    },
    {
      "nct_id": "NCT01547299",
      "title": "Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Dutasteride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 52,
      "start_date": "2012-03-31",
      "completion_date": "2013-11-30",
      "has_results": true,
      "last_update_posted_date": "2018-10-23",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01547299"
    },
    {
      "nct_id": "NCT05263921",
      "title": "Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioavailability"
      ],
      "interventions": [
        {
          "name": "PF-07321332/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-03-10",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05263921"
    },
    {
      "nct_id": "NCT00711204",
      "title": "Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Severe Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Donepezil Hydrochloride (Aricept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-12-10",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00711204"
    },
    {
      "nct_id": "NCT01169467",
      "title": "Cerebral Perfusion Pressure Using Precedex and Other Sedatives",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endotracheal Intubation",
        "Continuous IV Sedation",
        "ICP Monitoring"
      ],
      "interventions": [
        {
          "name": "Standard-of-Care plus Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Standard-of-Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2009-10",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-11-02",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169467"
    },
    {
      "nct_id": "NCT00424892",
      "title": "Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Desvenlafaxine Sustained Release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": null,
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2007-12-06",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 59,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00424892"
    },
    {
      "nct_id": "NCT05857644",
      "title": "A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Diseases",
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "PF-07923568",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 28,
      "start_date": "2023-06-07",
      "completion_date": "2024-02-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 3,
      "location_summary": "Tustin, California • Orlando, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05857644"
    },
    {
      "nct_id": "NCT04008784",
      "title": "Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Crisaborole 2% Topical Application Ointment [EUCRISA]",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone Acetonide 0.1% Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clinical Research Center of the Carolinas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "2 Years to 79 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-09-16",
      "completion_date": "2020-09-08",
      "has_results": false,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-10-26T22:14:19.431Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04008784"
    }
  ]
}